BG12..I'm getting worried

Quote

Anonymous

Guest
My kols are starting to question a few things

1. lack of trust with very superficial disclosure of any data so far...specifically how many patients did not tolerate titration period

2. PML risk given psoriasis expetrience in Germany...with much shorter treatment periods

3. Impact of flushing..relates to 1 above...so far we have only released incidence not prevelance of this AE...its becoming obvious management is manipulating data which is leading to a lack of trust here. Some KOLs are saying as many as 40% of their patienmts couldnt tolerate drug during phase 3, others are saying its no ig deal...responses are all over the map but our lack of disclosure is seriously hurting TRUST.

wake up management dont F this up
 


Seriously....look at the way Tysabri's intro was handled. And now ask yourself if upper management wouldn't manipulate the data for BG 12. Our reputation for questionable data with MS drugs is well known in the field...and it isn't something to be proud of!
 


Anonymous said:
My kols are starting to question a few things

1. lack of trust with very superficial disclosure of any data so far...specifically how many patients did not tolerate titration period

2. PML risk given psoriasis expetrience in Germany...with much shorter treatment periods

3. Impact of flushing..relates to 1 above...so far we have only released incidence not prevelance of this AE...its becoming obvious management is manipulating data which is leading to a lack of trust here. Some KOLs are saying as many as 40% of their patienmts couldnt tolerate drug during phase 3, others are saying its no ig deal...responses are all over the map but our lack of disclosure is seriously hurting TRUST.

wake up management dont F this up
Click to expand...

We all know that PML isn't fatal anymore, so nothing to worry about there.
 








Anonymous said:
My kols are starting to question a few things

1. lack of trust with very superficial disclosure of any data so far...specifically how many patients did not tolerate titration period

2. PML risk given psoriasis expetrience in Germany...with much shorter treatment periods

3. Impact of flushing..relates to 1 above...so far we have only released incidence not prevelance of this AE...its becoming obvious management is manipulating data which is leading to a lack of trust here. Some KOLs are saying as many as 40% of their patienmts couldnt tolerate drug during phase 3, others are saying its no ig deal...responses are all over the map but our lack of disclosure is seriously hurting TRUST.

wake up management dont F this up[/QUOTE.

Seriously hurting TRUST? How long have you worked for this outfit? Just fire up the honorarium machine. Neurologists don't care about data and trust. They want cash and Biogen is king of that game. Just look at Avonex . The fact that this marginally effective, comparatively speaking, MS therapy is used at all says every thing you need to know about Biogen marketing and greedy neurologists. BG 12 is just fine no matter what
Click to expand...
 


Seriously hurting TRUST? How long have you worked for this outfit? Just fire up the honorarium machine. Neurologists don't care about data and trust. They want cash and Biogen is king of that game. Just look at Avonex . The fact that this marginally effective, comparatively speaking, MS therapy is used at all says every thing you need to know about Biogen marketing and greedy neurologists. BG 12 is just fine no matter what
Click to expand...

What was that about Biogen's big interest in the health of MS patients??!! Heh, heh...yeah right! Biogen has one intere$t and one intere$t only...let's not fool ourselves folks.
 


Anonymous said:
Anonymous said:
My kols are starting to question a few things

1. lack of trust with very superficial disclosure of any data so far...specifically how many patients did not tolerate titration period

2. PML risk given psoriasis expetrience in Germany...with much shorter treatment periods

3. Impact of flushing..relates to 1 above...so far we have only released incidence not prevelance of this AE...its becoming obvious management is manipulating data which is leading to a lack of trust here. Some KOLs are saying as many as 40% of their patienmts couldnt tolerate drug during phase 3, others are saying its no ig deal...responses are all over the map but our lack of disclosure is seriously hurting TRUST.

wake up management dont F this up[/QUOTE.

Seriously hurting TRUST? How long have you worked for this outfit? Just fire up the honorarium machine. Neurologists don't care about data and trust. They want cash and Biogen is king of that game. Just look at Avonex . The fact that this marginally effective, comparatively speaking, MS therapy is used at all says every thing you need to know about Biogen marketing and greedy neurologists. BG 12 is just fine no matter what
Click to expand...

original poster here

true that brother (or sister)

Ive been around for a loong time both comercial and medical in 5 different TA's

these Ms ologists so called physicians are the biggest unethical clueless sluts I have seen on the physician side by a long shot. Thanks for grounding me..BG12 will be fine cause these jokers dont give a shit bout their patients....just their pockets
Click to expand...
 


these Ms ologists so called physicians are the biggest unethical clueless sluts I have seen on the physician side by a long shot. Thanks for grounding me..BG12 will be fine cause these jokers dont give a shit bout their patients....just their pockets
Click to expand...

As someone who does not work in the world of pharma, I've been say this about many docs AND Biogen for many years. Thank you (someone on the inside) for confirming my comments and to those who have bad mouthed me about this for a long time, GFY.
 


Who would come to these boards with bulleted data points about fears of potential side effects if they were launching a product? By the way, every other company is outspending BI right now because they anticipate blockbuster status for the new product. The industry in general spends a lot of money on marketing, period!
 


Anonymous said:
Who would come to these boards with bulleted data points about fears of potential side effects if they were launching a product? By the way, every other company is outspending BI right now because they anticipate blockbuster status for the new product. The industry in general spends a lot of money on marketing, period!
Click to expand...

Far more on marketing than any other expense yet the companies tell us they charge so much for the drugs because of the large research costs. Yea, sure!
 


I agree....Biogen is KING of MS marketing & paying off doc's (Foley) . Don't kid yourselves...everyone with a brain left to Genzyme just so they could sleep at night including the Mormons.
 








Anonymous said:
2. PML risk given psoriasis expetrience in Germany...with much shorter treatment periods
Click to expand...

Am I correct in understanding that BG12 is a German drug repackaged and relabeled as an American drug, kinda like my car is for all intents and purposes, a Toyota, yet redesigned a little on the interior and relabeled as a Chevrolet?
 


Anonymous said:
What planet are you living on??!!
Click to expand...

Biogen wouldn't lie. It's funny how the company says 80% of the PML patients survive .....with varies degrees of disability. Survival for Biogen is 6 months. If a pt is diagnosed with PML if they live more then 6 months that is considered survival. If you look at those same pts a year out 70-80% have died and only 20-30% still alive. So your life span is 6 months.
 


Anonymous said:
Biogen wouldn't lie. It's funny how the company says 80% of the PML patients survive .....with varies degrees of disability. Survival for Biogen is 6 months. If a pt is diagnosed with PML if they live more then 6 months that is considered survival. If you look at those same pts a year out 70-80% have died and only 20-30% still alive. So your life span is 6 months.
Click to expand...

You are a liar. Completely false statistics.
 





Write your reply...
Top Bottom
Back
Quote